Out Fox The $treet

Updated - March 7, 2026 HIMS  closed up 40% in AHs on a surprise twist with  NVO  agreeing to a partnership.  Hims was a $30 last month and the stock trades at only 1x 2026 sales estimates of $2.7 billion.  -Novo Nordisk ( NVO ) is planning to sell its obesity drugs on the telehealth platform run by Hims & Hers Health ( HIMS ) as part of a partnership between the two firms, Bloomberg reported, citing a person familiar with the matter. -The companies are set to announce the deal as early as Monday, according to the person who sought anonymity, as the information is not yet public. -A spokesperson for the Danish drugmaker told Bloomberg, “We are always in conversation with companies that can help improve patient access to FDA-approved medicines for people living with chronic diseases. These talks happen on an ongoing basis.” HIMS was not available for comments outside regular business hours. Looking for a portfolio of ideas like this one? Members of Out Fox Th...

  Hims & Hers Health, Inc. remains ultra Bullish despite a near 80% drawdown from 52-week highs, with growth initiatives firmly on track. HIMS projects 2026 revenues of $2.7–$2.9 billion, above consensus, and expects strong subscriber growth in weight loss offerings despite temporary GLP-1 headwinds. The Eucalyptus acquisition is set to add at least $200 million to 2026 revenues, positioning HIMS for a $3.25–$4 billion annualized run rate entering 2027. Regulatory risks from DoJ, FDA, and SEC persist, but HIMS emphasizes GLP-1s are only one part of its diversified health platform, making the stock cheap at only 1x sales. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More » Hims & Hers Health, Inc. ( HIMS ) has seen the stock make a huge reversal after an initial post-Q4 selloff. The online health and wellness platform is full-speed ahead on growth initiatives while the stock ...

Hims & Hers Health trades at yearly lows amid market hysteria over compounded oral Wegovy and regulatory scrutiny. The online health platform is not a GLP-1-centric company; weight-loss sales are forecast at only 30% of 2025 revenue, with a broader focus on preventative care and platform growth. Recent FDA and Novo Nordisk actions should have limited impact, as HIMS already pulled the oral Wegovy, and the market has overreacted to worst-case scenarios. The stock is cheap, trading with a current valuation of just 1.5x 2026 revenue, while platform expansion and new treatments suggest conservative analyst forecasts. Hims & Hers Health, Inc.  ( HIMS ) slumped to yearly lows as the market fed into investor hysteria over a compounded version of the Wegovy pill. The health and wellness platform isn’t focused on GLP-1s, as the goal is proactive preventative  care, but the market is reacting to the FDA aggressively working towards the company not offering compounded GLP-1s. My...

Update - Nov. 13, 2025 Hims & Hers Health has slipped below key support around $40. The online health and wellness platform is getting incredibly cheap at just 3x '26 sales estimates of $2.8 billion. The company even just launched Labs, a preventative care lab test.  Original article posted on Oct. 20 Hims & Hers Health launched menopause and low testosterone products in the last month, expanding its addressable market and supporting its $6.5 billion 2030 revenue target. Recent product launches, including at-home lab testing, are expected to boost ARPU and drive significant revenue growth for HIMS in coming years. The stock market over reacted to planned stock sells by the CEO. Current weakness in HIMS shares presents a buying opportunity, with the stock trading at just 4x projected 2026 sales and robust long-term potential. Looking for a portfolio of ideas like this one? Members of Out Fox The Street get exclusive access to our subscriber-only portfolios.  Learn More ...

  Hims & Hers Health has traded very volatile over the last year as the market misunderstands the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scrutiny, but this is industry-wide and not unique to the company. The platform is rapidly growing subscribers, launching new offerings, and targeting large under-penetrated markets domestically and internationally on a path to hitting a $6.5B 2030 sales target. The stock trades at a low valuation relative to its growth at only 4x '26 sales targets, making current levels a compelling buying opportunity. Hims & Hers Health, Inc. ( NYSE: HIMS ) has hit a bumpy ride over the last year, with the stock stuck in a range from $40 to $70. The online health and wellness platform has faced a lot of questions regarding compounding GLP-1s, with the latest  news being a letter from the FDA. My  investment thesis  remains ultra Bullish on the stock, as the company moves forward w...

Updated - Feb. 21, 2025 Hims & Hers Health isn't reliant on GLP-1 shortages. Not sure why news reports keep making this false claim, but the stock is down 20% today on the FDA ending the semagultide shortage status.  -The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs for two more months as supply conditions for the GLP-1s improve after an official end to their shortage. -Earlier in the day, the agency declared that the nationwide shortage of the highly popular GLP-1s, collectively known as semaglutide, is resolved after nearly three years. -“The FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” the regulator said. -Hims & Hers (NYSE:HIMS), which made compounded versions of semaglutide amid the shortage, lost billions of dollars in market cap in reaction as the telehea...

Update - May 21  Hims has slumped some after the initial 30% rally on Monday. The telehealth company should benefit from offering a compound GLP-1 version at a discounted price. The big question is the financial impact. The stock only trades at 3x '24 sales targets making Hims intriguing on any further dip.  -Hims & Hers Health (NYSE:HIMS) is offering customers access to compounded versions of Novo Nordisk's (NVO) semaglutide -- the active drug in its weight loss medication Wegovy -- at a fraction of the cost of the brand-name version. -The company said plans for injections of its compounded semaglutide -- which is also sold as the type 2 diabetes med Ozempic -- start at $199 a month. It is also offering a $79 a month plan for an oral version of semaglutide. That is also known as Novo's diabetes pill Rybelsus. Original article posted on May 7 Hims & Hers Health, Inc. is leading in personalized health and building a strong health and wellness platform, leading to str...

Updated Aug. 23, 2023 Hims continues trending down. The stock remains appealing on these dips with software like margins and growth rates.  Update Aug. 17, 2023 Hims & Hers continues to dip following another great earnings report. The online health and wellness platform continues to shift towards profitable precisions treatments, but the market has missed the shift. Definitely a stock to watch for when Hims hits the lows.  Original article published on Aug. 16  Hims & Hers Health, Inc. falls despite a strong Q2 '23 earnings report. The company remains on the path to a 2025 revenue target of $1.2+ billion. The stock is cheap at 1.3x forward EV/S targets for a high gross margin business. Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments  here »   Despite another strong quarter,  Hims & Hers Health, Inc.  ( NYSE: HIMS ) stock fell after  Q2 '23 results  beat consensus estimates. ...

Out Fox The Street members get exclusive access to our real-world portfolios. See all of our investments  here »   Update - July 28, 2023  Cowen with a bull call on Hims with a price target of $11 after the stock recently traded at $12. Nice the greatest bull call, but it sure beats the short report.  TD Cowen initiated its coverage of the digital healthcare platform Hims & Hers Health ( NYSE: HIMS ) with an Outperform rating and a $11 per share target on Friday, citing a disconnect between the company’s prospects and the valuation. Noting that Hims & Hers ( HIMS ) is set to expand at over 78% CAGR in 2019–2023E, analyst Jonna Kim argues that the company’s $1.2B revenue target for 2025, indicating over 22% CAGR, "implies a significant slowdown." Update - July 13, 2023 Kinda of a joke short report on Hims & Hers today, any stock could face a 25% hit. Heck, we view Apple  as having the potential for 50% downside. The stock has bounced off strong suppor...